Doldrums....

Geez we are stuck in the doldrums aren't we....
Personally, I'm not sure the true potential of immuteps research into the lag-3 gene and again
its trial program as both a stand alone treatment and as an adjuvant by its prime candidate
"efti" is understood generally by the market and those investors who judge something by the
companys share price in the instance......

The "instance" is the direct result of trial data available but gives no credence to
potential and indeed interest from the biotechs well and truly ensconced in the top tier
of research companies....

There is no consideration of one Frederic Treibel and his pursuance of his beliefs
in his research dating decades back but only recently accepted by the broader
research sector....To say it has been broadly accepted of late as a worthy gene
worth looking into, is an understatement...

Everything is geared around trial results, we over the next 12 months are
going to receive a lot of data, eagerly awaited by the company and a lot
like me who are no doubt bemused by current SP.....

Character building stuff this...